Morning Light Treatment for Traumatic Stress: The Role of Amygdala Reactivity
NCT ID: NCT04117347
Last Updated: 2024-12-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2020-01-24
2023-03-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Light therapy A via the Re-Timer®
-15 minutes/day
Light therapy A via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Light therapy B via the Re-Timer®
-30 minutes/day
Light therapy B via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Light therapy C via the Re-Timer®
-60 minutes/day
Light therapy C via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Light therapy A via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Light therapy B via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Light therapy C via the Re-Timer®
Subjects will conduct light treatment in the mornings at home.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal or corrected to normal vision
* Right-handed
* Fluency in English
* Physically able to travel for study visit attendance
Exclusion Criteria
* Severe hearing problem
* Intellectual disability or serious cognitive impairment
* Inability to tolerate enclosed spaces (e.g. the MRI machine)
* Ferrous-containing metals within the body
* Pregnant, trying to get pregnant, or breastfeeding
* Epilepsy
* Other research participation
* Frequent number of special events during study period (weddings, concerts, exams, etc.)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helen Burgess
Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen Burgess
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Burgess HJ, Rizvydeen M, Huizenga B, Prasad M, Bahl S, Duval ER, Kim HM, Phan KL, Liberzon I, Abelson J, Klumpp H, Horwitz A, Mooney A, Raglan GB, Zalta AK. A 4-week morning light treatment reduces amygdala reactivity and clinical symptoms in adults with traumatic stress. Psychiatry Res. 2024 Dec;342:116209. doi: 10.1016/j.psychres.2024.116209. Epub 2024 Sep 21.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00161267
Identifier Type: -
Identifier Source: org_study_id